Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced ...

CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad ...

Shares of Verastem, Inc. (NASDAQ:VSTM – Get Free Report) have earned an average recommendation of “Buy” from the eight ...

Immuneering Corp. Class A ( (IMRX) ) has released its Q3 earnings. Here is a breakdown of the information Immuneering Corp. Class A presented ...

In the oral presentation, the investigators reported ongoing improved survival compared to historical controls, with 3 out of ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune ...

- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug ...

Candel Therapeutics (CADL) announced preclinical results and therapeutic potential of CAN-3110 in the Ras-Raf pathway altered melanoma model. The data will be presented at the Society for ...

Avutometinib is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF potentially creating a more complete and durable anti-tumour response through maximal RAS/MAPK pathway ...

Schematic models of the core of MAPK/ERK pathway and human eIF3 complex. (A) The MAPK/ERK pathway activation by growth factors and receptor tyrosine kinases (RTKs). RTKs signal through GRB2-Sos and ...